Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Assembly Biosciences Inc

ASMB
Current price
0.74 USD +0.019 USD (+2.64%)
Last closed 0.72 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 47 047 716 USD
Yield for 12 month -43.08 %
Week
Month
Year
ASMB
21.11.2021 - 28.11.2021

Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research, as well as a partnership with Gilead Sciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California. Address: 331 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Analytics

WallStreet Target Price

3 USD

P/E ratio

Dividend Yield

Current Year

Last Year

+6 254 000 USD

Current Quarter

Last Quarter

Current Year

Last Year

+6 254 000 USD

Current Quarter

Last Quarter

Key Figures ASMB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -75 286 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -54.71 %
PEG Ratio
Return On Equity TTM -100.84 %
Wall Street Target Price 3 USD
Revenue TTM
Book Value 0.79 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100 %
Dividend Yield
Gross Profit TTM -63 895 000 USD
Earnings Share -1.43 USD
Diluted Eps TTM -1.43 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ASMB

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ASMB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:5
Payout Ratio
Last Split Date 14.07.2014
Dividend Date

Stock Valuation ASMB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 5.8492
Price Sales TTM 3.9591
Enterprise Value EBITDA -0.0227
Price Book MRQ 1.1263

Financials ASMB

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ASMB

For 52 weeks

0.64 USD 1.78 USD
50 Day MA 0.81 USD
Shares Short Prior Month 785 294
200 Day MA 1 USD
Short Ratio 0.13
Shares Short 649 655
Short Percent 1 %